维普中文期刊产品整合服务
385篇 您的检索式:作者名="Peter MD"
    题名 作者 年代 出处 被引量
1世界各地动脉粥样硬化血栓形成门诊患者心血管危险因素的流行及诊治情况显示文摘背景:动脉粥样硬化血栓形成是导致心血管疾病和死亡的主要原因。至今,尚无国际数据库阐述动脉粥样硬化血栓形成患者动脉硬化危险因素的特征和治疗强度。 目的:确定动脉粥样硬化危险因素的发生及治疗在世界许多国家是否具有可比性。设计、地点及参试者:“降低动脉粥样硬化血栓形成保持健康研究”(Reduction of Atherothrombosis for Continued Health,REACH)搜集了动脉粥样硬化危险因素及治疗情况的数据。从2003年到2004年,44个国家、5473位内科从业医师总共发现67888例年龄≥45岁的动脉病患者(冠心病[coronaryartery disease,CAD],n=40258;脑血管病,n=18843;周围动脉病,n=8273)或≥3个动脉粥样硬化血栓形成危险因素(n=12389)。主要观测指标:动脉粥样硬化危险因素的基线发生率、药物应用情况及危险因素控制程度。结果:全世界动脉粥样硬化血栓形成患者具有相似的危险因素,即高血压(81.8%)、高胆固醇血症(72.4%)以及糖尿病(44.3%)的比例高。超重(39.8%)、肥胖(26.6%)以及病态肥胖(3.6%)的发生率在大部分地区相似,但是以北美最高(超重:37.1%,肥胖:36.5%,病态肥胖:5.8%;与其他地区比较P〈0.001)。患者采用他汀(总共69.4%;范围:从脑血管病的56.4%到CAD的76.2%)、抗血小板治疗(总共78.6%;范围:从≥3个危险因素的53.9%到CAD的85.6%)及其他循证(降低危险)普遍不足。确诊有血管病的患者在吸烟者为数可观(14.4%)。高血压病治疗不足(基线50.0%血压升高)、高血糖诊断不足(4.9%)以及空腹血糖受损(其中36.5%不知已有糖尿病)均很常见。在有症状的动脉粥样硬化血栓形成患者中,15.9%是有症状的多血管疾病患者。 结论:这项当代大型国际数据库研究显示,在世界许多地区典型心血管危险因素的发生是一致且常见的,但是大多治疗不足、控制不得力。Deepak L. Bhatt, MD P. Gabriel Steg, MD E. Magnus Ohman, MD Alan T. Hirsch, MD Yasuo Ikeda, MD Jean-Louis Mas, MD Shinya Goto, MD Chlau-Suong Liau, MD, PhD Alain J. Richard, MD, PhD Joachim Roether, MD Peter W. F. Wilson, MD 徐成斌(译) 2007美国医学会杂志(中文版)2007,26,1:5
2Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy显示文摘Gauri R. Varadhachary MD Eric P. Tamm MD James L. Abbruzzese MD Henry Q. Xiong MD Christopher H. Crane MD Huamin Wang MD Jeffrey E. Lee MD Peter W. T. Pisters MD Douglas B. Evans MD Robert A. Wolff MD 2006Annals of Surgical Oncology2006,,8:4
3Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy显示文摘Peter Kornprat MD William R. Jarnagin MD FACS Mithat Gonen PhD Ronald P. DeMatteo MD FACS Yuman Fong MD FACS Leslie H. Blumgart MD FACS FRCS Michael D'Angelica MD FACS 2007Annals of Surgical Oncology2007,,3:3
4Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival显示文摘Chandrajit P. Raut MD Karen R. Cleary MD Gregg A. Staerkel MD James L. Abbruzzese MD Robert A. Wolff MD Jeffrey H. Lee MD Jean-Nicolas Vauthey MD Jeffrey E. Lee MD Peter W. T. Pisters MD Douglas B. Evans MD 2006Annals of Surgical Oncology2006,,4:3
5A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial显示文摘Julio Garcia-Aguilar MD PhD Qian Shi PhD Charles R. Thomas MD Emily Chan MD PhD Peter Cataldo MD Jorge Marcet MD David Medich MD Alessio Pigazzi MD Samuel Oommen MD Mitchell C. Posner MD 2012Annals of Surgical Oncology2012,,2:2
6Role of Surgery Combined with Kinase Inhibition in the Management of Gastrointestinal Stromal Tumor (GIST)显示文摘Peter Hohenberger MD PhD Burton Eisenberg MD 2010Annals of Surgical Oncology2010,,10:2
7Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma显示文摘Shishir K. Maithel MD Stephen Maloney MD Corrine Winston MD Mithat G?nen PhD Michael I. D'Angelica MD Ronald P. DeMatteo MD William R. Jarnagin MD Murray F. Brennan MD Peter J. Allen MD 2008Annals of Surgical Oncology2008,,12:2
8Antivascular endothelial growth factor agentsand their development: therapeutic implications in ocular diseases显示文摘Peter K Kaiser MD 2006Am J Ophthalmol2006,142,:1
9Gastric Cancer Surgery in Elderly Patients显示文摘Stephen Gretschel MD Lope Estevez-Schwarz MD Michael Hünerbein MD Ulrike Schneider MD Peter M. Schlag MD PhD 2006World Journal of Surgery2006,,8:1
10Newborn surgical emergencies: gastrointestinal anomalies, abdominal wall defects 显示文摘Peter W Dillon MD Robert E 1993Pediatr Clin North Am1993,40,6:1
11Oncological Superiority of Hilar En Bloc Resection for the Treatment of Hilar Cholangiocarcinoma显示文摘Peter Neuhaus MD Armin Thelen MD Sven Jonas MD Gero Puhl MD Timm Denecke MD Wilfried Veltzke-Schlieker MD Daniel Seehofer MD 2012Annals of Surgical Oncology2012,,5:1
12Neoadjuvant chemotherapy for the management of ovarian cancer显示文摘Peter E Schwartz MD 0,,04:1
13Can the Proximal Femoral Nail be Improved?显示文摘Inger B. 1 8 Phone Fax e-mail: Schipper MD PhD Roger K. J. Simmermacher Tobias Hüttl R?bi Frigg Peter Messmer Michael Schütz Andreas Lenich Chris Werken 2005European Journal of Trauma2005,,3:1
14Cost and Utilization Impact of a Clinical Pathway for Patients Undergoing Pancreaticoduodenectomy显示文摘Geoffrey A. Porter MD Peter W. T. Pisters MD Carol Mansyur MA Annette Bisanz MPH Kim Reyna MBA Pam Stanford RN Jeffrey E. Lee MD Douglas B. Evans MD 2000Annals of Surgical Oncology2000,,7:1
15An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus显示文摘Mayer B Davidson MD Anne L Peters MD 1997The American Journal of Medicine1997,,1:1
16In vitro degradation of porous poly( L-lactic acid) foams显示文摘Lu L Peter SJ Lyman MD 2000Biomaterials2000,21,:1
17Retinoids as generalized regulators of cellular growth and differentiation 显示文摘Peter JA Davies MD Jamas PB 1988Am J Med Sci1988,296,:1
18Interleukin- 10 messenger ribonucleic acid in human placenta: Implications of a role for interleukin-10 in fetal allograft protection显示文摘 Peter L Rady MD 1995Am J Obstet Gynecol1995,173,:1
19Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists 显示文摘Peter Libby Jorge Plutzky MD 2007Cardiology2007,99,2:1
20Surgical Treatment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Evans et al.显示文摘Reid B. Adams MD Peter J. Allen MD 2009Annals of Surgical Oncology2009,,7:1
返回顶部 每页显示:
共20页 首页 上一页 第1页 下一页 末页 /20 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费